Filing status
- Accounts due
- 31 December 2027
- Last accounts
- 31 March 2026
- Conf. stmt due
- 12 May 2027
- Last conf. stmt
- 28 April 2026
Re-Aim Therapeutics Ltd
- Incorporated
- 29 April 2024 (2 years)
- Industry
- Research and experimental development on biotechnology (72110)
- Directors
- Iain McgillDhavalkumar PatelRoel Bulthuis
- Owned by
- Syncona Portfolio LimitedAsher Maroof
- Accounts type
- Small
- Region
- South East
- Address
- Innovation Building Old Campus RoadRoosevelt DriveOxfordOX3 7FZ
Officers 6 active
Officer details are public data from the Companies House register.
Mcgill, Iain
Director · Appointed 16 April 2026
British
Born May 1972 (54)
Patel, Dhavalkumar, Dr
Director · Appointed 17 February 2026
American
Born August 1961 (65)
Bulthuis, Roel
Director · Appointed 2 October 2025
Dutch
Born March 1976 (50)
Director · Appointed 2 October 2025
Also at Kesmalea Therapeutics Limited · more companies
British
Born November 1975
Director · Appointed 2 October 2025
French
Born December 1993 (32)
Maroof, Asher, Dr
Director · Appointed 29 April 2024
British
Born September 1976 (50)
Officer history (2 former)
16 April 2026
Appointed Mcgill, Iain as Director
18 February 2026
Resigned Tsai, John as Director
17 February 2026
Appointed Patel, Dhavalkumar, Dr as Director
2 October 2025
Appointed Bulthuis, Roel as Director
2 October 2025
2 October 2025
2 October 2025
Appointed Tsai, John as Director
2 October 2025
Resigned Goldstein, Jason as Director
29 April 2024
Appointed Maroof, Asher, Dr as Director
29 April 2024
Appointed Goldstein, Jason as Director
Ownership 2 active
People and entities with significant control, from the Companies House PSC register
Syncona Portfolio Limited
Corporate entity · Notified 3 October 2025
Owns 25–50% of shares
Holds 25–50% of voting rights
Non Cellular Company
Reg. no. 62778
Asher Maroof
Individual · Notified 29 April 2024
Owns 25–50% of shares
Holds 25–50% of voting rights
British
Born September 1976 (50)
Financials
Balance sheet as at 31 March 2026 · small accounts
- Cash
- £5,122,556
- Current Ratio
- 32.7x
Trend
Shareholder Funds
Balance sheet detail
| 2026 | 2025 | |
|---|---|---|
| Fixed Assets | £64,719 | £2,369 |
| Current Assets | £5,434,191 | £62,231 |
| Debtors | £311,635 | £33,939 |
| Cash | £5,122,556 | £28,292 |
| Creditors (< 1 year) | £166,356 | |
| Net Current Assets | £5,267,835 | (£16,430) |
| Shareholder Funds | £5,332,554 | (£14,061) |
Filings
Filing history not loaded yet. See it on Companies House
Other companies in this industry
By trade and location
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →